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Primary Prevention of 
Sudden Cardiac Death in 
Adults with Trans position 
of the Great Arteries:
A Review of Implantable 
Cardioverter-Defibrillator Placement
Transposition of the great arteries encompasses a set of structural congenital cardiac le-
sions that has in common ventriculoarterial discordance. Primarily because of advances 
in medical and surgical care, an increasing number of children born with this anomaly are 
surviving into adulthood. Depending upon the subtype of lesion or the particular correc-
tive surgery that the patient might have undergone, this group of adult congenital heart 
disease patients constitutes a relatively new population with unique medical sequelae. 
Among the more common and difficult to manage are cardiac arrhythmias and other se-
quelae that can lead to sudden cardiac death. To date, the question of whether implant-
able cardioverter-defibrillators should be placed in this cohort as a preventive measure 
to abort sudden death has largely gone unanswered. Therefore, we review the available 
literature surrounding this issue. (Tex Heart Inst J 2015;42(4):309-18)
C ardiac arrhythmias are a considerable problem among adult congenital heart disease (ACHD) patients.1 Arrhythmias have been identified as the leading cause of morbidity and hospitalization, and sudden cardiac death (SCD) is 
known to be the most common cause of death in this group.1-4 Sudden cardiac death 
in ACHD patients typically occurs in the 3rd to 4th decade of life, and patients with 
ACHD are at up to a 100-fold increased risk of SCD when compared with age-
matched members of a control group.4,5
 Within the spectrum of congenital heart disease (CHD), certain lesions have been 
identified as conveying a particularly elevated risk of SCD.5 Among these is transposi-
tion of the great arteries (TGA),5 which accounts for 5% to 7% of all congenital car-
diac malformations.6 The Centers for Disease Control and Prevention estimates that, 
in the United States, approximately 1,900 babies are born annually with TGA, an 
incidence of about 5 in every 10,000 live births.7 The increased risk for SCD in TGA 
patients, specifically, is thought to result from a combination of sequelae consequent to 
various surgical corrections, long-standing right ventricular (RV) strain, and abnormal 
electrical architecture secondary to both genetic and physiologic stress.8-18 Together, 
these abnormalities can lead to cardiac failure and arrhythmias as the affected child 
grows into adulthood.8-18 In consequence, the indications for and value of implantable 
cardioverter-defibrillators (ICD) in adult TGA patients is an area of considerable in-
terest. Here we review the available data pertaining to ICD implantation for primary 
prevention of SCD in adult TGA patients.
Background
Congenital TGA encompasses a group of structural cardiac lesions that has in com-
mon ventriculoarterial discordance—a state in which the aorta arises from the mor-
phologic RV and the pulmonary artery (PA) arises from the morphologic left ventricle 
(LV).14 As an entity, TGA is grossly subdivided into the dextro-type (D-TGA, or 
complete TGA) and the levo-type (L-TGA, or congenitally corrected TGA) depend-
ing upon the type of ventricular looping that occurs during cardiogenesis.19 These 
malformations frequently coexist with any number of congenital anomalies, includ-
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ing ventricular septal defect (VSD), atrial septal defect 
(ASD), patent ductus arteriosus (PDA), and Ebstein’s 
anomaly of the tricuspid valve.14,19
 Complete TGA is the more prevalent of the 2 forms 
of TGA.3,14 That defect is characterized by atrioventricu-
lar (AV) concordance: the left atrium (LA) empties into 
the morphologic LV and the right atrium (RA) empties 
into the morphologic RV, with ventriculoarterial dis-
cordance.14 This results in 2 parallel circulatory systems, 
with pulmonary venous effluent returning again to the 
lungs and systemic venous return being pumped once 
again to the peripheral circulation.14,20 Maintenance of 
oxygenation in the untreated state requires the presence 
of a shunt lesion via an intracardiac defect (for example, 
ASD, VSD, or PDA), which enables mixing of the sys-
temic and pulmonary circulations.14,20 Even if a shunt 
is present, however, the typical patient is profoundly 
cyanotic at birth.20
 Complete transposition generally requires a palliative 
intervention at birth if a congenital shunt is not present 
and, ultimately, corrective surgery in early infancy to 
aid in patient survival.19-21 Such surgical interventions for 
D-TGA are considered reparative, not curative.3 Until 
the early 1980s, the best corrective surgery for D-TGA 
patients was the atrial switch procedure, whereby sys-
temic venous return was routed across the atrial septum 
to the morphologic LV, and pulmonary venous return 
was routed to the morphologic RV via intra-atrial baf-
fles14,20 (Fig. 1). The first iteration of such surgeries (orig-
inally described in 1959), was the Senning procedure, 
which used native atrial tissue to create the baff le.14,22 
Subsequently, the Mustard procedure (first performed 
in 1964) used Dacron or pericardial tissue to achieve the 
same result.3,23 These atrial switch procedures created 
AV discordance and left in place the ventriculoarterial 
discordance characteristic of D-TGA.20 They also left 
the morphologic RV responsible for maintenance of the 
systemic circulation in these patients, frequently leading 
to pump failure over time.20,24,25 Partly as a consequence 
of these drawbacks of the atrial switch, the Mustard and 
Senning procedures were largely abandoned by the late 
1980s in favor of arterial switch operations (either the 
Jatene or Rastelli, depending on the patient’s anatomy), 
which in effect restored ventriculoarterial concordance 
in D-TGA3,14,17 (Fig. 1). On early analysis, the arterial 
switch procedure appears to decrease the predisposition 
to pump failure and late arrhythmias that characterize 
the atrial switch1,20,26-28; however, the cohort of D-TGA 
patients who have undergone arterial switch procedures 
is currently only in early adulthood.12,14
 Conversely, L-TGA is characterized by AV discor-
dance with concomitant ventriculoarterial discor-
dance.3,14 As a result, the LA empties into the RV, which 
then pumps blood to the aorta, and the RA empties 
into the LV, which then pumps blood to the PA.14 This 
configuration arises from a malrotation of the ventricles 
during cardiac organogenesis, leaving the morphologic 
RV in the leftward and posterior position and the mor-
phologic LV in the rightward and anterior position.19 In 
the absence of other defects, affected patients will not be 
cyanotic at birth.14,29 Consequently, their lesions might 
be missed until they develop heart failure or undergo 
cardiac imaging for an unrelated issue later in life.14,29 
If not associated with other significant defects, L-TGA 
does not require immediate surgical correction.29 Si-
multaneous atrial and arterial switch procedures in 
these patients have been performed with the goal of 
reestablishing AV and ventriculoarterial concordance, 
in order to preserve the morphologic LV as the systemic 
ventricle.30-33 However, because of the high perioperative 
mortality rate and possible adverse sequelae of baff le 
creation associated with this “double switch” proce-
dure—in comparison with the relatively benign clinical 
course of uncorrected L-TGA throughout the first 4 to 
5 decades of life—this surgery is relatively rare.34
Risk of Arrhythmia and Sudden Cardiac Death
In improving long-term survival rates, the corrective 
surgical procedures performed for TGA in the pediat-
ric population have created a subset of ACHD patients 
with unique long-term postoperative complications 
and medical issues.35-37 From the cardiac standpoint, 
the most recognized sequelae in this group are arrhyth-
mias, RV dysfunction, and SCD.3,12,16,36-43 Among these, 
arrhythmias are a leading cause of morbidity and hospi-
talization in TGA patients.12,13,36 A review by Deal44 pub-
lished in 2011 revealed that TGA patients experience a 
variety of arrhythmias, which include sinus node dys-
function, AV nodal block, supraventricular tachycardia 
(SVT), and ventricular tachycardia (VT). Depending 
upon the subtype of TGA (D- or L-) and the correc-
tive surgery performed (atrial switch, arterial switch, 
or double switch) the incidence of these arrhythmias 
among TGA patients varies.44 In particular, Deal’s re-
view showed that adult patients with D-TGA who 
underwent arterial switch operations (for example, the 
Jatene) had a lower incidence of arrhythmias overall 
than did those who had undergone atrial switch pro-
cedures.44 This higher arrhythmic risk after the atrial 
switch has been attributed to lines of conduction block 
and isthmuses of slowed conduction (hence a substrate 
for reentry) caused by the extensive atrial scarring as-
sociated with the Mustard and Senning operations.44 
In a large meta-analysis directly comparing outcomes 
of patients who had undergone Senning and Mustard 
procedures, sinus node dysfunction was more often ob-
served in those with Mustard corrections, but the data 
regarding atrial tachyarrhythmias were not conclusively 
different.45
 Transposition patients are also known to be at in-
creased risk of life-threatening arrhythmias.4,12,18,46-48 
Sudden cardiac death is the leading cause of late death 
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in patients with repaired cyanotic CHD (including 
surgically corrected D-TGA).4,5 The overall incidence 
of SCD in this particular group has been estimated to 
be approximately 1 per 1,000 patient-years, and the risk 
of SCD in ACHD patients is 25 to 100 times greater 
than that in the general population.4,5 In 1998, Silka and 
colleagues retrospectively investigated the frequency of 
SCD among residents in the state of Oregon who had 
undergone surgical treatment for CHD between 1958 
and 1996.5 The authors found a marked diagnosis-de-
pendent difference in the relative risk of late SCD among 
patients with repaired CHD.5 The subgroup of D-TGA 
patients, specifically, had an SCD incidence of 4.9 per 
1,000 patient-years, second only to the rate of congenital 
aortic stenosis and 3-fold greater than that seen in tetral-
ogy of Fallot (TOF) patients.5 Of note, all but one of 
the D-TGA patients had previously undergone Mustard 
procedures.5 Earlier series performed by Gelatt and as-
sociates12 and Gwelling and colleagues16 showed a similar 
risk for SCD in D-TGA patients who had undergone 
Mustard procedures. It is now recognized that among 
ACHD patients, those with TGA who have had some 
form of atrial switch operation are at the highest risk of 
SCD, with an actuarial incidence approaching 10% by 
20 years after surgery.5,12,17 In contrast, long-term and ar-
rhythmia-free survival rates appear to be much better in 
Fig. 1  Schematic illustration of surgical interventions for the 2 subtypes of transposition of the great arteries. A) Reparative surgeries 
for D-TGA include the atrial switch, the arterial switch, and the VSD baffle + conduit operation. The atrial switch (Mustard or Senning) 
uses an intra-atrial baffle to redirect the systemic venous return to the morphologic left ventricle and the pulmonary venous return 
to the morphologic right ventricle, effectively creating atrioventricular discordance. The arterial switch procedure (Jatene) involves 
transsection of the aorta and the pulmonary artery, followed by re-anastomosis at the opposite roots, restoring ventriculoarterial con-
cordance. The VSD baffle + conduit (Rastelli) operation creates a valved conduit from the right ventricle to the pulmonary artery and a 
baffle from the left ventricle across a ventricular septal defect to the aortic valve. B) Surgical intervention for L-TGA includes the “double 
switch” operation wherein simultaneous atrial redirection and arterial switch procedures are performed, again resulting in the presence 
of an atrial baffle. 
 
Ao = aorta; D-TGA = dextro-transposition of the great arteries; LA = left atrium; L-TGA = levo-transposition of the great arteries; LV = left 
ventricle; PA = pulmonary artery; RA = right atrium; RV = right ventricle; VSD = ventricular septal defect
A B
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D-TGA patients treated with the newer arterial switch 
operation.27 Whether this benefit is attributable to he-
modynamically unstable SVT or VT resulting from 
atrial scarring after atrial redirection surgery or, rather, 
to eventual systemic ventricular failure is currently un-
clear.49
 Because of the high prevalence of SCD associated 
with all subtypes of ACHD, there has been great inter-
est in identifying clinical risk factors that predispose pa-
tients in this group to cardiac events.50 Signal-averaged 
electrocardiograms (SAECG) and T-wave alternans 
(TWA) exercise studies have been investigated on a 
very limited basis as means of identifying those at risk 
for the development of life-threatening arrhythmias 
within the CHD population.51,52 Results of one pro-
spective study did suggest that positive SAECG results 
connote the presence of a slow conduction substrate 
and the risk of monomorphic VT in those patients 
who had previously undergone right ventriculotomy 
for repair of CHD.51 Ultimately, SAECG and TWA 
do not accurately predict SCD risk in this group, and 
neither investigative technique is routinely used in clini-
cal practice. As with other forms of CHD, investigators 
have attempted to define clinical predictors of SCD, 
specif ically in D-TGA patients who have undergone 
atrial switch procedures.15,18,49,53 Most have suggested 
that both atrial tachyarrhythmias and RV failure (in-
cluding RV dysfunction measured by echocardiography 
and heart failure indicated by symptoms) are risk fac-
tors for late SCD.12,18,49,53 Other studies have shown that 
the late development of spontaneous VT or ventricular 
fibrillation (VF) might be more prevalent in this patient 
population than has been reported.5,14,15 Risk factors for 
VT and SCD in these observational studies included a 
QRS duration ≥140 ms, an older age at surgical repair, 
and systemic ventricular dysfunction.15 More recently, a 
retrospective study of 89 TGA patients found that older 
age at intervention (either Mustard or Senning), surgery 
during an earlier year (median, 1971 vs 1975), and a 
history of atrial arrhythmias conveyed an increased risk 
of SCD within this group.54 Unfortunately, conclusive 
identification of the cause of SCD (for example, severe 
pump failure, poorly tolerated SVT, or ventricular ar-
rhythmia) and, therefore, formulation of a reliable and 
validated risk metric for its prediction remain elusive in 
this particular population.30,44
Implantable Cardioverter-Defibrillator 
Placement in TGA Patients
Antiarrhythmic agents, ablative techniques, and implan-
tation of a permanent pacemaker or internal defibrillator 
have been used to treat a wide spectrum of arrhythmic 
conditions in ACHD patients.1,3,55-57 Although multiple 
pharmacotherapeutic and interventional options are 
regularly applied, few high-quality data exist on the 
specific indications for and efficacy of these treatments 
i`n any diagnostic group among this cohort.3,56 Rather, 
general guiding principles for the management of car-
diac patients without CHD (but with similar medical 
problems) tend to dictate decision-making.3,56
 Multiple strategies for the prevention and manage-
ment of malignant arrhythmias have been implemented 
over the years. Currently, the ICD has assumed a prin-
cipal role,50 but the indications for ICD placement in 
CHD patients remain controversial: expert opinion 
varies, and there are few additional data upon which 
to base recommendations.50 For secondary prevention, 
decisions to place an ICD in both pediatric and adult 
CHD patients are fairly straightforward.50 It is gener-
ally agreed that such patients can benefit from device 
implantation if they have survived cardiac arrest or a 
sustained episode of VT with hemodynamic com-
promise—provided that neither a definitive reversible 
cause nor a terminal illness with a life expectancy of less 
than one year exists.50,56 On the other hand, the decision 
to place an ICD for the purposes of primary prevention 
in an asymptomatic or minimally symptomatic patient 
is less clear. Increasing numbers of case reports, studies, 
and reviews have recently focused on outcomes of ICD 
placement in pediatric and adult CHD patients.1,3,9,50,55-65 
Some authors58,62 have attempted to create risk-stratifi-
cation schemata for determining which patients might 
benefit from ICD placement for primary prevention, 
either through retrospective analysis of SCD incidence 
in a group of patients without a device, or through ret-
rospective analysis of clinical predictors of appropriate 
shock delivery among patients with ICDs in place.
 Unfortunately, increased frequency of device compli-
cations, suboptimal risk-stratification schemes to guide 
patient selection, uncertainty regarding eff icacy, and 
challenging patient anatomy make the introduction of 
an ICD for primary prevention in CHD patients an 
extremely complex decision.50 Although it is not un-
usual for ICDs to be implanted for primary prevention 
in symptomatic patients with failing systemic ventri-
cles, the validity of extrapolating data from the primary 
prevention trials of patients without CHD, and then 
applying them to the ACHD cohort, is questionable.57 
Moreover, standard indications to implant an ICD for 
primary prevention are present only in a minority of 
ACHD patients who undergo such procedures.55,56
 Sudden cardiac death is known to be the most fre-
quent cause of death among TGA patients who have 
previously undergone an atrial switch, with an observed 
incidence between 2% and 15%.5,13,21,43,53,66-69 However, 
identifying a high-risk subgroup within this popula-
tion has also proved to be difficult.49 Bradyarrhythmias 
were once thought to be the primary trigger of SCD in 
this group. That theory was questioned and ultimately 
was refuted, when retrospective evidence showed that 
pacemakers did not confer protection from sudden 
death.38,39
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 The largest analysis of ICD implantation in D-TGA 
patients (specifically) was published in 2008 by Khairy 
and colleagues.49 This multicenter study attempted 
to identify clinical predictors of appropriate shock, 
determine the rates of appropriate and inappropriate 
shock delivery, and characterize complications in this 
group.49 Retrospective data were collected on a total of 
37 D-TGA patients (mean age, 28 ± 7.6 yr) who had 
previously undergone an atrial switch procedure. Ap-
proximately 62% of these patients had ICDs placed for 
primary prevention, whereas the rest had devices im-
planted for secondary prevention. Justifications for pri-
mary prevention implantation in this cohort included 
presyncope, syncope, palpitations, nonsustained VT 
(NSVT), systemic RV ejection fraction (EF) ≤0.35, 
QRS duration ≥180 ms, and inducible sustained VT 
on electrophysiologic study.49 Those with ICDs placed 
for primary prevention tended to be older at the time 
of implantation, had a higher prevalence of NSVT, and 
were more likely to exhibit moderate or severe RV sys-
tolic dysfunction than were their counterparts whose 
devices had been placed for secondary prevention. Ul-
timately, the investigators concluded that a high rate of 
appropriate shocks occurred among patients with ICDs 
placed for secondary prevention, but that the rate of 
such shocks was exceedingly low in patients with de-
vices placed for primary prevention. Other germane 
findings of this study were that patients not prescribed 
β-blockers experienced higher rates of appropriate 
shocks, that inducible VT on electrophysiologic study 
was not predictive of appropriate shocks, and that supra-
ventricular arrhythmias can themselves lead to ventricu-
lar tachyarrhythmias.49 Aside from this isolated study 
by Khairy and colleagues,49 data regarding outcomes of 
ICD implantation in this patient population are largely 
limited to case reports70 and small series,61,71 or to stud-
ies of CHD patients as a pooled group.58-62,64,65,72 Unfor-
tunately, subgroup analysis by underlying congenital 
anomaly was not routinely performed in the latter. 
Therefore, specific outcomes in D- and L-TGA patients 
are difficult to evaluate. One case series71 did identify 
5 D-TGA patients who, after Mustard surgery, under-
went ICD placement for primary prevention at a single 
institution and found that no shocks were delivered to 
the subjects during a follow-up period of 24 months. 
Because no shocks were delivered, no judgments could 
be made in regard to the risk for appropriate shock.71 
Data on the benefit of ICD therapy in adult congeni-
tal patients with, specifically, surgically treated or un-
treated L-TGA are even more limited. Although current 
dogma holds that systemic ventricular dysfunction and 
history of atrial arrhythmias in TGA patients who have 
undergone some form of intra-atrial redirection surgery 
are indicative of increased risk of SCD, the data remain 
less than definitive for the placement of ICDs for pri-
mary prevention.
 Device implantation in TGA patients who have un-
dergone atrial redirection surgery is not without chal-
lenge and risk, and the hazard of inappropriate ICD 
placement should not be underestimated. The potential 
for inappropriate shocks delivered from a device placed 
either for primary or secondary prevention and the re-
sultant anguish posed to individuals within this group 
are very real.50,73-77 Implantable cardioverter-defibrillators 
are known to confer survival benefit among patients 
at risk for SCD with primary prevention indications 
(low LV ejection fraction with a structurally normal 
heart).78-82 However, inappropriate shocks—whether 
for atrial arrhythmias with rapid ventricular conduc-
tion or for abnormal sensing—result in multiple adverse 
effects that can include impaired quality of life, psychi-
atric disturbances, and even provocation of nonfatal or 
fatal ventricular arrhythmias.83 Because TGA patients 
are predisposed to such rhythm disturbances, the im-
plantation of ICDs for primary prevention in this group 
is not entirely benign. In fact, in a recently published 
trial of 59 ACHD patients who had ICDs placed for 
both primary and secondary prevention, adults with 
non-TOF congenital heart lesions (D-TGA, L-TGA, 
double-outlet RV, Shone complex, isolated pulmonary 
atresia, total anomalous pulmonary venous return, 
AV canal defect, and secundum ASD) received fewer 
appropriate ICD therapies but had an equivalent rate 
of inappropriate ICD therapies, when compared with 
their TOF counterparts over a median follow-up period 
of 3.2 years.72 Although subanalysis of ICD therapies 
was not performed among the non-TOF patients, these 
f indings do suggest that the benefit of ICD implan-
tation can vary by underlying ACHD lesion (TOF vs 
non-TOF) and that the increased relative risk of ICD 
shocks and complications might outweigh the useful-
ness of devices placed for traditional indications in the 
non-TOF population.72
 In addition to the diff iculty of identifying clinical 
risk factors for SCD within the TGA patient popula-
tion and the propensity for inappropriate shock delivery 
once ICDs are placed, one must consider complications 
surrounding the implantation and maintenance of de-
vices when conducting a risk–benefit analysis of ICD 
placement for primary prevention.49,50 Because of the 
altered anatomy, created not only by the defect itself 
but by the baffle repair, technical challenges to the im-
plantation of leads can be considerable.3,57 Baff le ob-
struction has been reported in 36% of TGA patients, 
with systemic venous pathway obstruction occurring 
3.5 times more frequently in Mustard than in Senning 
repairs.45 Consequently, vascular access limitations 
might preclude transvenous lead placement that re-
quires epicardial systems.1,53,55,57 If a transvenous device 
is successfully placed, the chronic presence of a bulky 
lead in the superior limb of the atrial baff le can pre-
dispose patients to baffle stenosis84-86 (Fig. 2). In addi-
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tion, because of the relative position of the ventricles in 
D-TGA after an atrial switch, the systemic ventricle is 
not interposed between the device coil and generator 
as it normally would be in traditional transvenous ICD 
lead placement.71 This is thought to have a significant 
effect on defibrillation thresholds and eff icacy.71,87 Fi-
nally, in ACHD patients who have had ICDs placed 
for either primary or secondary prevention, lead failure 
is the most frequently reported device-related compli-
cation.50,55 This is probably due to a combination of 
unusual anatomy and the younger average age of the 
cohort in whom these devices are implanted, predispos-
ing leads to either passive or traumatic fracture.50
 Very few current data exist on the usefulness and 
benefit of epicardial devices or subcutaneous arrays for 
cardiac defibrillation within the ACHD patient popula-
tion. Evidence suggests that subcutaneous arrays are less 
effective than transvenous devices with regard to defi-
brillation thresholds.71 This drawback might be miti-
gated by selecting patients with smaller body sizes and 
incorporating intrathoracic electrodes in those chosen 
for subcutaneous systems.71 Although epicardial devices 
do not appear to be inferior to transvenous defibrillators 
for the primary prevention of SCD (according to the 
limited data available for this group), the placement of 
epicardial patches requires an open-chest procedure.71 
Because the implantation of such systems introduces an 
increased procedural risk and can lead to adverse conse-
quences, including constriction and bleeding, epicardial 
patches have largely been abandoned.55
 In 2008, 2 review articles published in Circulation: 
Arrhythmia and Electrophysiology considered the mat-
ter of whether patients with CHD who had a systemic 
ventricular EF of <0.30 should undergo prophylactic 
ICD implantation.73,88 From the opposing viewpoint, 
Triedman73 posited that CHD patients are significantly 
different from populations in other primary prevention 
studies63 and that current evidence suggesting a lack of 
appropriate shocks60,61,64,89 and an adverse effect on qual-
ity of life75-77 argue against routine ICD placement for 
primary prevention in ACHD patients with EF <0.30. 
He suggested, rather, that ventricular function should 
be a crucial input in a multifactorial, patient-specif ic 
approach to risk evaluation in this population.73
 From the supportive viewpoint, Silka and Bar-Co-
hen88 asserted that there is a def inite association be-
tween advanced systemic ventricular dysfunction and 
SCD in specif ic forms of postoperative CHD (chief 
among them, D-TGA after atrial switch repair). In con-
sideration of the advances in ICD technology and the 
benefits that MADIT II and SCD-HeFT revealed in 
non-CHD patients with an EF <0.30,78,81 the authors 
contended that ICD placement for primary prevention 
in ACHD patients with failing systemic ventricles has 
a high probability of benefit.88
 Although the above reviews concerned ICD im-
plantation in CHD patients in general, rather than in 
TGA patients in particular, many of the conclusions 
were drawn from evidence that included TGA subjects. 
Hence the question of whether TGA patients should 
routinely receive ICDs for primary prophylaxis remains 
highly complicated (Table I). The lack of high-quality 
clinical evidence for the examination of outcomes in a 
large number of TGA patients with ICD placement is 
the most substantial impediment to resolving this issue. 
Studies similar to that performed by Khairy and col-
leagues49 would probably provide essential data both on 
the causes that underlie SCD (that is, pump failure, 
SVT, or VT/VF) and on the efficacy of ICD therapy 
in preventing those events. Only from this kind of in-
formation will recommendations arise that are likely to 
benefit this patient population. On the basis of current 
evidence, the primary disadvantages to ICD placement 
in this group appear to be a high frequency of inappro-
priate shocks, difficulty in device implantation, compli-
cations that include (but are not limited to) lead fracture 
and failure, and uncertain efficacy in preventing SCD. 
As ICD technology improves and procedural strides 
are made in the application of such devices, some of 
these issues might become less problematic. Neverthe-
less, without resolution of the fundamental uncertainty 
Fig. 2  Lateral fluoroscopic view of a patient with baffle stenosis, 
a consequence of pacemaker lead placement through an atrial 
baffle. The pacemaker generator is seen giving rise to the atrial 
and ventricular leads, both of which travel through the original 
atrial baffle. The stenotic portion of the baffle (arrow) has caused 
dilation of the superior vena cava and of the azygos venous 
system. 
 
A = atrial pacemaker lead; AV = azygos vein; PM = pacemaker 
generator; SVC = superior vena cava; V = ventricular pacemaker 
lead
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regarding the eff icacy of ICDs in this cohort, ICD 
implantation will not and should not be viewed as the 
standard of care; rather, it should be applied on a case-
by-case basis. When considering an ICD for primary 
prevention, a number of factors, including the presence 
of atrial or ventricular arrhythmias, systemic ventricu-
lar dysfunction, and the severity of symptoms should 
be included in the evaluation of a TGA patient before 
proceeding with device placement. Family support, life-
style, and psychological burden should be factored into 
the decision-making process as well.
 The implantation of ICDs in TGA patients as sec-
ondary prevention, however, appears to be supported 
by the sparse data that are available. Khairy and col-
leagues49 indicated that patients with ICD implants for 
secondary prevention were significantly more likely to 
experience arrhythmia, and subsequently to receive ap-
propriate therapy. This, in combination with data indi-
cating that antiarrhythmic drugs do not confer the same 
protection,81 argues in favor of ICD implantation in this 
subpopulation. These patients probably should be pre-
scribed concurrent β-blockers, because there is some in-
dication that β-blockade suppresses primary ventricular 
arrhythmias and affords protection against appropriate 
shocks in those who already have devices in place.49
Conclusion
As with many other questions in ACHD, that of ICD 
implantation for primary prevention in TGA patients 
remains unresolved. Furthermore, as the number of 
patients who have previously undergone atrial switch 
procedures has probably peaked and eventually will be 
surpassed by those with arterial switch repairs, the risk 
of SCD in TGA patients is going to change. All fac-
tors indicate that the probability of this complicated 
question’s being answered in a broadly applicable way 
is remote. For the foreseeable future, ICD implantation 
in TGA patients will continue to be recommended on 
a case-by-case basis, with careful consideration of the 
multiple facets of the decision.
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